Sreepadma Sonty
Neurology with Special Qualifications in Child Neurology · Doral, FLNPI 1154559045
Payments from drug & device makers
Across 156 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$736
- UCB, Inc.$420
- Neurocrine Biosciences, Inc.$286
- Neurelis, Inc.$180
- Lundbeck LLC$161
- Novartis$159
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,446100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $736 |
| UCB, Inc. | 11 | $420 |
| Neurocrine Biosciences, Inc. | 18 | $286 |
| Neurelis, Inc. | 9 | $180 |
| Lundbeck LLC | 7 | $161 |
| Novartis | 5 | $159 |
| Supernus Pharmaceuticals, Inc. | 3 | $156 |
| Amgen | 6 | $138 |
| Sumitomo Pharma America, Inc. | 5 | $123 |
| GE HealthCare | 7 | $116 |
| Octapharma USA, Inc. | 4 | $104 |
| Upsher-smith Laboratories LLC | 5 | $103 |
| Pfizer | 6 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $97 |
| Aprecia Pharmaceuticals, LLC | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Boston Scientific | 1 | $55 |
| Lilly USA, LLC | 3 | $47 |
| Merz Pharmaceuticals, LLC | 2 | $43 |
| SK Life Science, Inc. | 2 | $42 |
| Tanabe Pharma America, Inc. | 2 | $38 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $33 |
| Microtransponder, Inc. | 1 | $28 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Livanova USA, Inc. | 1 | $21 |
| Aquestive Therapeutics, Inc. | 1 | $18 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,446 in reported general payments places this provider in the 45th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobazam | 24 | $2,360 |
| Lacosamide | 11 | $1,874 |
| Gabapentin | 19 | $420 |
| Aripiprazole | 12 | $153 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Doral
- Paul WinnerWest Palm Beach$18.4M
- James RenfroeGulf Breeze$2.9M
- Walter MartinezWest Palm Beach$1.9M
- Weldon MauneyGulf Breeze$1.3M
- Ian MillerMiami$1.1M
- Jose FerreiraTampa$876K
- Ronald DavisWinter Park$873K
- Peter KangGainesville$607K
- Omer Abdul HamidOrlando$467K
- Migvis MonduyMiami$455K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.